Clinical Protocol and Data Management (CPDM) The Clinical Trials Office (CTO) at the University of Arizona Cancer Center (UACC) is the operational equivalent of the CPDM. It provides a centralized and comprehensive infrastructure for the conduct of clinical trials involving cancer patients. The CTO oversees institutional, externally peer-reviewed, National Clinical Trials Network (NCTN), and industry-sponsored studies. While treatment interventional trials are of major interest to the Cancer Center, the CTO also assists in the execution of trials with a broad range of other objectives, including diagnostics, cancer screening, basic science, health services, cancer prevention, and supportive care. The research supported by the CTO serves both adult and pediatric populations. The UACC has invested substantial support in the CTO to enable the management of important interventional trials, their associated accruals, and the increasing complexity of clinical trials. The CTO functions as a central administrative office for the implementation and conduct of internally and externally funded adult and pediatric oncology studies. Review and approval of protocols is performed by the Disease-Oriented Teams (DOTs) or Multidisciplinary Teams (MDTs), and the Scientific Review Committee and is required of UACC investigations prior to activation. There are nine designated DOTs and four that evaluate new protocols and monitor accrual for ongoing studies. The CTO also maintains and assures the quality of data regarding cancer clinical trial activation and accrual throughout the University. The CTO is led by well-qualified leadership and is subdivided into four major research support groups: 1) Review Committee and Regulatory Support Management; 2) Clinical Research Finance and Administrative Management; 3) Clinical Research, Data, and Biospecimen Management; and 4) Research Compliance / Quality Management. Clinical research support staff are positioned to effectively manage all processes of the trial lifecycle, and the CTO is organized in a manner that facilitates continuous improvement. The CTO has defined timelines for study activation that are important to maintain efficiency and effectiveness in conducting clinical research. The CTO maintains standard operating procedures (SOPs) and workflows that describe work processes conducted by the staff. The CTO facilitates the adoption of technology to increase operational efficiencies and quality management practices for supporting clinical research. The SOPs of the CTO stipulate that the CTO will conduct regularly scheduled internal reviews of protocol records. Since the last review period, the CTO expanded its capacity significantly to more appropriately oversee the trials currently open, and in preparation for a significant expansion of new faculty recruitment, the Phase I Program, and the community-based network of affiliate organizations. The UACC CTO adheres to the NIH policy that women and members of minority groups and their subpopulations be included in clinical research and supports increasing access to clinical research for children, consistent with the NIH recommendations. Data and safety monitoring support is provided for clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-40
Application #
9969502
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
40
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Kobes, Joseph E; Georgiev, George I; Louis, Anthony V et al. (2018) A Comparison of Iron Oxide Particles and Silica Particles for Tracking Organ Recellularization. Mol Imaging 17:1536012118787322
Kelly, K R; Espitia, C M; Zhao, W et al. (2018) Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32:230-233
Downs, Charles A; Johnson, Nicholle M; Tsaprailis, George et al. (2018) RAGE-induced changes in the proteome of alveolar epithelial cells. J Proteomics 177:11-20
Sun, Virginia; Wendel, Christopher S; Demark-Wahnefried, Wendy et al. (2018) Diet and Behavior Modifications by Long-term Rectal Cancer Survivors to Manage Bowel Dysfunction-Associated Symptoms. Nutr Cancer :1-11
Mushtaq, Adeela; Kapoor, Vikas; Latif, Azka et al. (2018) Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol 125:1-11
Rak, Michael A; Buehler, Jason; Zeltzer, Sebastian et al. (2018) Human Cytomegalovirus UL135 Interacts with Host Adaptor Proteins To Regulate Epidermal Growth Factor Receptor and Reactivation from Latency. J Virol 92:
Rojo de la Vega, Montserrat; Zhang, Donna D; Wondrak, Georg T (2018) Topical Bixin Confers NRF2-Dependent Protection Against Photodamage and Hair Graying in Mouse Skin. Front Pharmacol 9:287
Bea, Jennifer W; de Heer, Hendrik Dirk; Valdez, Luis et al. (2018) Physical Activity among Navajo Cancer Survivors: A Qualitative Study. Am Indian Alsk Native Ment Health Res 25:54-73
Siyahian, Aida; Malik, Saad Ullah; Mushtaq, Adeela et al. (2018) Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 24:1483-1489
Stanton, Annette L; Wiley, Joshua F; Krull, Jennifer L et al. (2018) Cancer-related coping processes as predictors of depressive symptoms, trajectories, and episodes. J Consult Clin Psychol 86:820-830

Showing the most recent 10 out of 1336 publications